CRITICAL THERAPEUTICS INC

Form 4

October 11, 2005

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Warren Howland Shaw

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

CRITICAL THERAPEUTICS INC [CRTX]

(Check all applicable)

(Last)

(City)

(First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)

10/11/2005

_X__ Director Officer (give title

10% Owner Other (specify

C/O CRITICAL THERAPEUTICS.

(Street)

(State)

INC., 60 WESTVIEW STREET

4. If Amendment, Date Original

Filed(Month/Day/Year)

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

(Zip)

LEXINGTON, MA 02421

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| | | | | | | | 1 | , | • |
|--------------------------------------|---|---|---|--------|--|--|---|---|---|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. 4. Securities Acquired Transaction(A) or Disposed of Code (D) (Instr. 8) (Instr. 3, 4 and 5) | | 5. Amount of Securities Beneficially Owned Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | Code V | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | |
| Common Stock | 10/11/2005 | | S(1) | 2,100 | D | \$ 8.49 | 304,144 | D | |
| Common Stock | 10/11/2005 | | S(1) | 1,500 | D | \$ 8.49 | 302,644 | D | |
| Common Stock | 10/11/2005 | | S(1) | 1,200 | D | \$ 8.49 | 301,444 | D | |
| Common Stock | 10/11/2005 | | S(1) | 1,100 | D | \$ 8.5 | 300,344 | D | |
| Common Stock | 10/11/2005 | | S <u>(1)</u> | 500 | D | \$ 8.57 | 299,844 | D | |

Edgar Filing: CRITICAL THERAPEUTICS INC - Form 4

| Common Stock | 10/11/2005 | S <u>(1)</u> | 500 | D | \$ 8.54 299,344 | D |
|-----------------|------------|--------------|-----|---|--------------------|---|
| Common Stock | 10/11/2005 | S <u>(1)</u> | 400 | D | \$ 8.5 298,944 | D |
| Common Stock | 10/11/2005 | S <u>(1)</u> | 400 | D | \$ 8.48 298,544 | D |
| Common Stock | 10/11/2005 | S(1) | 300 | D | \$ 8.51 298,244 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 9. Nu Deriv Secu Bene Own Follo Repo Trans (Insti

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of | 2. | 3. Transaction Date | 3A. Deemed | 4. | 5. | 6. Date Exerc | cisable and | 7. Title | e and | 8. Price of | |
|-------------|-------------|---------------------|--------------------|------------|------------|---------------|-------------|----------|----------|-------------|--|
| Derivative | Conversion | (Month/Day/Year) | Execution Date, if | Transact | ionNumber | Expiration D | ate | Amou | nt of | Derivative | |
| Security | or Exercise | | any | Code | of | (Month/Day/ | Year) | Underl | lying | Security | |
| (Instr. 3) | Price of | | (Month/Day/Year) | (Instr. 8) | Derivative | e | | Securit | ties | (Instr. 5) | |
| | Derivative | | | | Securities | 3 | | (Instr. | 3 and 4) | | |
| | Security | | | | Acquired | | | | | | |
| | | | | | (A) or | | | | | | |
| | | | | | Disposed | | | | | | |
| | | | | | of (D) | | | | | | |
| | | | | | (Instr. 3, | | | | | | |
| | | | | | 4, and 5) | | | | | | |
| | | | | | | | | | Amount | | |
| | | | | | | | | | or | | |
| | | | | | | Date | Expiration | | Number | | |
| | | | | | | Exercisable | Date | | of | | |
| | | | | Code V | (A) (D) | | | | Shares | | |
| | | | | | (1-) | | | | ~ | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|---|---------------|-----------|---------|-------|--|--|--|
| . 0 | Director | 10% Owner | Officer | Other | | | |
| Warren Howland Shaw C/O CRITICAL THERAPEUTICS, INC. 60 WESTVIEW STREET LEXINGTON, MA 02421 | X | | | | | | |

Signatures

/s/ Scott B. Townsend, 10/11/2005 Attorney-in-Fact

**Signature of Reporting Person Date

2 Reporting Owners

Edgar Filing: CRITICAL THERAPEUTICS INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2005.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.